Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Synageva BioPharma Corp Reaffirms FY 2013 Earnings Guidance


Tuesday, 29 Oct 2013 04:45pm EDT 

Synageva BioPharma Corp reiterated its previous net operating loss guidance of between $87 million and $97 million for fiscal 2013. The net loss is primarily due to investments necessary to support global clinical development of the lead program sebelipase alfa, further development of SBC-103, expansion of the global clinical, medical affairs and commercial infrastructure, expansion of manufacturing capabilities, as well as advancement of Synageva's other pipeline programs. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report net income of $(89) million for fiscal 2013. 

Company Quote

91.28
1.56 +1.74%
26 Dec 2014